OpenAI Acquires Orchestra Bio to Advance AI-Powered Drug Development
Key Facts
OpenAI confirmed its acquisition of Orchestra Bio, a platform for coordinating drug development at biopharmaceutical companies, according to a company statement. The deal brings Orchestra's team and technology together with Rosalind, OpenAI's ecosystem of life sciences research models and tools. The stated goal includes building AI agents that help teams connect scientific findings with the studies, decisions and steps needed to advance a potential drug. The intended scope of work thus extends to coordinating drug development programs, including their interconnected activities and schedules. Orchestra said in its statement announcing the move that it began operating 4 years ago to help biotechnology and pharmaceutical teams develop drug programs.
OpenAI's statement illustrates the complexities Orchestra addresses with a manufacturing example: a failed production batch could delay the start of a clinical trial. The platform helps teams analyze dependencies between program activities and timelines, including the link between manufacturing readiness and trial launches. Orchestra, for its part, identifies planning, coordination and analysis within drug development programs as tasks for AI agents. The company said: "Agents can handle planning, coordination and analysis." The platform leaves decisions requiring specialist expertise to scientists and program leaders, according to the division of responsibilities outlined by the company.
The acquisition follows OpenAI's introduction of GPT Rosalind, a model specializing in life sciences research, on 16 April 2026. The company estimates that moving from therapeutic target discovery to regulatory approval for a new drug in the United States takes an average of about 10 to 15 years. On research tools, it says the life sciences research add-on provides access to more than 50 public databases, literature sources and biological tools. These resources include databases covering multiple levels of biological information, alongside sources and tools dedicated to research. On the use of the technology in the pharmaceutical sector, Reuters quoted industry officials as saying AI has yet to fully deliver on its promises in the hardest task: discovering important new molecules.
In an update dated 11 September 2026, OpenAI announced that GPT Rosalind had moved out of research preview. The model became available globally to eligible organizations through the company's trusted access program. The Rosalind workspace remains in research preview, bringing curated scientific tools together in one workspace. The company also offers an academic plan for eligible laboratories, including up to 30 free seats on its standard business plan. Free access lasts up to 12 months, under the academic plan's announced terms.
In the same field, Anthropic launched a program in beta to verify the eligibility of users of life sciences applications. The program initially targets teams and organizations, providing access with safeguards appropriate for biological work, according to the company's announcement. Anthropic also announced the creation of a life sciences research group and laboratory. The group and laboratory focus on fundamental biological research using Claude, as part of the company's research activities in the field. The work includes experimental validation of hypotheses, according to Anthropic's announcement of the group and laboratory.
On the deployment of the technology within pharmaceutical companies, Novo Nordisk announced a strategic partnership with OpenAI on 14 April 2026. The partnership formed part of an expansion in Novo Nordisk's use of AI across its operations, according to the company's announcement. The announced plan includes integrating the technology into the drugmaker's operations. The partnership aims to achieve full integration by the end of 2026, according to Novo Nordisk. The plan thus sets the end of the year as the target for completing integration under the partnership.